Abatacept initiation in rheumatoid arthritis and the risk of cancer: a population-based comparative cohort study.
| Autor: | Montastruc, François, Renoux, Christel, Dell'Aniello, Sophie, Simon, Teresa A, Azoulay, Laurent, Hudson, Marie, Suissa, Samy |
|---|---|
| Předmět: |
LYMPHOMA risk factors
MELANOMA TUMOR diagnosis TUMOR risk factors SKIN tumors LUNG tumors BREAST tumor risk factors AGE distribution COMPARATIVE studies CONFIDENCE intervals LONGITUDINAL method MEDICARE RHEUMATOID arthritis DISEASE incidence PROPORTIONAL hazards models ABATACEPT ODDS ratio THERAPEUTICS CANCER risk factors |
| Zdroj: | Rheumatology; Apr2019, Vol. 58 Issue 4, p683-691, 9p, 1 Black and White Photograph, 1 Diagram, 3 Charts, 2 Graphs |
| Abstrakt: | Objective To assess whether abatacept as initial biological DMARD (bDMARD) in the treatment of RA, when compared with other bDMARDs, is associated with an increased risk of cancer overall and by specific cancer sites (breast, lung, lymphoma, melanoma and non-melanoma skin cancer). Methods We performed a population-based cohort study among patients newly treated with bDMARDs within the US-based Truven MarketScan population and Supplemental US Medicare from 2007 to 2014. Cox proportional hazards models were used to estimate hazard ratios and 95% CIs of any cancer (and specific cancers) associated with initiation of abatacept, compared with initiation of other bDMARDs, adjusted for age and deciles of the propensity score. Results The cohort included 4328 patients on abatacept and 59 860 on other bDMARDs, of whom 409 and 4197 were diagnosed with any cancer during follow-up (incidence rates 4.76 per 100 per year and 3.41 per 100 per year, respectively). Compared with other bDMARDs, the use of abatacept was associated with an increased incidence of cancer overall (hazard ratio |
| Databáze: | Complementary Index |
| Externí odkaz: |
|